Abstract:Host-directed therapies aiming to strengthen the body's immune system, represent an underexplored opportunity to improve treatment of tuberculosis (TB). We have previously shown in Mycobacterium tuberculosis (Mtb)-infection models and clinical trials that treatment with the histone deacetylase (HDAC) inhibitor, phenylbutyrate (PBA), can restore Mtb-induced impairment of antimicrobial responses and improve clinical outcomes in pulmonary TB. In this study, we evaluated the efficacy of different groups of HDAC inhibitors to reduce Mtb growth in human immune cells. A panel of 21 selected HDAC inhibitors with different specificities that are known to modulate infection or inflammation was tested using high-content live-cell imaging and analysis. Monocyte-derived macrophages or bulk peripheral blood cells (PBMCs) were infected with the green fluorescent protein (GFP)-expressing Mtb strains H37Ra or H37Rv and treated with HDAC inhibitors in the micromolar range in parallel with a combination of the first-line antibiotics, rifampicin, and isoniazid. Host cell viability in HDAC inhibitor treated cell cultures was monitored with Cytotox-red. Seven HDAC inhibitors were identified that reduced Mtb growth in macrophages > 45–75% compared to average 40% for PBA. The most effective compounds were inhibitors of the class III HDAC proteins, the sirtuins. While these compounds may exhibit their effects by improving macrophage function, one of the sirtuin inhibitors, tenovin, was also highly effective in extracellular killing of Mtb bacilli. Antimicrobial synergy testing using checkerboard assays revealed additive effects between selected sirtuin inhibitors and subinhibitory concentrations of rifampicin or isoniazid. A customized macrophage RNA array including 23 genes associated with cytokines, chemokines and inflammation, suggested that Mtb-infected macrophages are differentially modulated by the sirtuin inhibitors as compared to PBA. Altogether, these results demonstrated that sirtuin inhibitors may be further explored as promising host-directed compounds to support immune functions and reduce intracellular growth of Mtb in human cells.

Myriocin enhances the clearance of M. tuberculosis by macrophages through the activation of PLIN2

Mycobacterium Tuberculosis Enhances Macrophage P-glycoprotein (MDR-1) Expression and Activity to Promote Intracellular Survival

MicroRNA-18b-5p Downregulation Favors <i>Mycobacterium tuberculosis</i> Clearance in Macrophages via HIF-1 by Promoting an Inflammatory Response

Mycobacterium Tuberculosis Rv0928 Protein Facilitates Macrophage Control of Mycobacterium Infection by Promoting Mitochondrial Intrinsic Apoptosis and ROS-mediated Inflammation

Down-regulation of Mir-20A-5p Triggers Cell Apoptosis to Facilitate Mycobacterial Clearance Through Targeting JNK2 in Human Macrophages.

Mycobacterium tuberculosis suppresses APLP2 expression to enhance its survival in macrophage

Mycobacterium Tuberculosis Mce2D Protein Blocks M1 Polarization in Macrophages by Inhibiting the ERK Signaling Pathway.

Microrna-146A Promotes Mycobacterial Survival in Macrophages Through Suppressing Nitric Oxide Production.

Pharmacological inhibition of macrophage triglyceride biosynthesis pathways does not improve control in infected mice

The impact of Mycobacterium tuberculosis on the macrophage cholesterol metabolism pathway

Effect of Mycobacterium Tuberculosis Enhancement of Macrophage P-Glycoprotein Expression and Activity on Intracellular Survival During Antituberculosis Drug Treatment

Small Molecule Targeting PPM1A Activates Autophagy for Mycobacterium tuberculosis Host-Directed Therapy

Sirtuin 7 Regulates Nitric Oxide Production and Apoptosis to Promote Mycobacterial Clearance in Macrophages

Sirtuin inhibitors reduce intracellular growth of M. tuberculosis in human macrophages via modulation of host cell immunity

MicroRNA-144-3p Inhibits Host Lipid Catabolism and Autophagy by Targeting PPARα and ABCA1 During Mycobacterium Tuberculosis Infection

Mir-4687-5p Affects Intracellular Survival of Mycobacterium Tuberculosis Through Its Regulation of NRAMP1 Expression in A549 Cells

Mycobacterium Tuberculosis PE_PGRS41 Enhances the Intracellular Survival of M. Smegmatis Within Macrophages Via Blocking Innate Immunity and Inhibition of Host Defense

Mycobacterium Tuberculosis Rv3402c Enhances Mycobacterial Survival Within Macrophages and Modulates the Host Pro-Inflammatory Cytokines Production Via NF-kappa B/ERK/p38 Signaling.

Interferon Regulatory Factor 1 Eliminates Mycobacteria by Suppressing P70 S6 Kinase Via Mechanistic Target of Rapamycin Signaling.

Host phospholipase C‐γ1 impairs phagocytosis and killing of mycobacteria by J774A.1 murine macrophages

Mycobacterium Tuberculosis Carrying a Rifampicin Drug Resistance Mutation Reprograms Macrophage Metabolism Through Cell Wall Lipid Changes